APRI (Aprinoia Therapeutics) Marketable Securities: $0.00 Mil (As of Dec. 2023)


What is Aprinoia Therapeutics Marketable Securities?

Aprinoia Therapeutics APRI Marketable Securities is $0.00 Mil as of Dec. 2023.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Aprinoia Therapeutics's Marketable Securities for the quarter that ended in Dec. 2023 was $0.00 Mil.

Aprinoia Therapeutics  (NAS:APRI) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Aprinoia Therapeutics Marketable Securities Related Terms

Aprinoia Therapeutics Marketable Securities Historical Data

* Premium members only.

The historical data trend for Aprinoia Therapeutics's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aprinoia Therapeutics Marketable Securities Chart

Aprinoia Therapeutics Annual Data
Trend Dec21 Dec22 Dec23
Marketable Securities
0.00 0.00 0.00

Aprinoia Therapeutics Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23
Marketable Securities 0.00 0.00 0.00 0.00 0.00

Aprinoia Therapeutics Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of $0.00 Mil mean?
Aprinoia Therapeutics (APRI) has a Marketable Securities of $0.00 Mil as of Dec. 2023. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Aprinoia Therapeutics and its competitors.
Is Aprinoia Therapeutics' Marketable Securities too high?
Aprinoia Therapeutics' current Marketable Securities is $0.00 Mil.
How does Aprinoia Therapeutics' Marketable Securities compare to ?
Aprinoia Therapeutics' Marketable Securities of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Biotechnology company?
A good Marketable Securities depends on the Biotechnology industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Aprinoia Therapeutics and its competitors. Aprinoia Therapeutics's current Marketable Securities is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aprinoia Therapeutics stock overvalued right now?
Aprinoia Therapeutics (APRI) has a current Marketable Securities of $0.00 Mil. The current Marketable Securities is $0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For Aprinoia Therapeutics (APRI), the current Marketable Securities is $0.00 Mil as of Dec. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Aprinoia Therapeutics Business Description

Comparable Companies
Address 245 Main Street, 2nd Floor, Cambridge, MA, USA, 02142
Aprinoia Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in protecting patients' brain health and changing clinical outcomes for a broad range of neurodegenerative diseases by developing novel, highly sensitive and selective diagnostic tools and novel therapeutics. Neurodegenerative diseases are relentless and largely fatal, resulting from progressive loss of nerve cells in the brain and, depending on the specific disorders, can affect a broad range of cognitive, behavioral, and motor functions, such as memory, thinking, speaking, walking, and breathing. It is developing several different diagnostic and therapeutic platforms such as abnormal protein aggregates of tau and alpha synuclein ("?-Syn") that are toxic to brain cells.